


GAU 1643



Attorney Docket No.: 5440.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
TECH CENTER 1600/2900
NOV - 1 AM 11:27
PATENT

In re Application of: Kauppinen et al.

Serial No.: 09/339,159

Group Art Unit: 1643

Filed: June 24, 1999

Examiner: TBA

For: Novel Mannanases

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Transmittal of Supplemental Information Disclosure Statement (in duplicate)
2. Supplemental Information Disclosure Statement
3. PTO-1449 Form
4. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

on October 26, 1999.

Carol McFarlane
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kauppinen et al.

Serial No.: 09/339,159

Group Art Unit: 1643

Filed: June 24, 1999

Examiner: TBA

For: Novel Mannanases

RECEIVED
TECH CENTER 1600/2900
99 NOV -1 AM 11:27

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Talbot et al., Applied and Environmental Microbiology, Vol. 56, pgs.

65163560
1449
000000
240.00 CH
10/29/99 6661/62/01
01 FC:126

3505-3510 (1990);

2. Mendoza et al., World Journal of Microbiology & Biotechnology, Vol. 10, pgs. 551-555 (1994);

3. PCT WO 97/11164;

4. PCT WO 91/18974;


5. PCT WO 94/25576; and

6. PCT WO 95/35362.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Date: October 26, 1999

Respectfully submitted,




Elias J. Lambiris, Reg. No. 33,728

Novo Nordisk of North America, Inc.

405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123



Attorney Docket No.:5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kauppinen et al.

Serial No.: 09/339,159

Group Art Unit: 1643

Filed: June 24, 1999

Examiner: TBA

For: Novel Mannanases

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement for the above-identified application. The Supplemental Information Disclosure Statement is being filed after the first Office Action on the merits.

Please charge the required fee, estimated to be \$240.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: October 26, 1999

Respectfully submitted,

Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123